179 related articles for article (PubMed ID: 29222349)
1. Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.
Nikiphorou E; van der Heijde D; Norton S; Landewé RB; Molto A; Dougados M; Van den Bosch FE; Ramiro S
Ann Rheum Dis; 2018 Mar; 77(3):405-411. PubMed ID: 29222349
[TBL] [Abstract][Full Text] [Related]
2. Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA).
Putrik P; Ramiro S; Moltó A; Keszei AP; Norton S; Dougados M; van der Heijde D; Landewé RBM; Boonen A
Ann Rheum Dis; 2019 Apr; 78(4):486-493. PubMed ID: 30674477
[TBL] [Abstract][Full Text] [Related]
3. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.
Bergstra SA; Branco JC; Vega-Morales D; Salomon-Escoto K; Govind N; Allaart CF; Landewé RBM
Ann Rheum Dis; 2018 Oct; 77(10):1413-1420. PubMed ID: 29980576
[TBL] [Abstract][Full Text] [Related]
4. The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study.
Bakker P; Moltó A; Etcheto A; Van den Bosch F; Landewé R; van Gaalen F; Dougados M; van der Heijde D
Arthritis Res Ther; 2017 May; 19(1):96. PubMed ID: 28511725
[TBL] [Abstract][Full Text] [Related]
5. Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study.
Rodrigues Manica S; Sepriano A; Ramiro S; Pimentel Santos F; Putrik P; Nikiphorou E; Norton S; Molto A; Dougados M; van der Heijde D; Landewé RBM; van den Bosch FE; Boonen A
Ann Rheum Dis; 2018 Sep; 77(9):1303-1310. PubMed ID: 29860232
[TBL] [Abstract][Full Text] [Related]
6. Inequities in access to biologic and synthetic DMARDs across 46 European countries.
Putrik P; Ramiro S; Kvien TK; Sokka T; Pavlova M; Uhlig T; Boonen A;
Ann Rheum Dis; 2014 Jan; 73(1):198-206. PubMed ID: 23467636
[TBL] [Abstract][Full Text] [Related]
7. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
Putrik P; Ramiro S; Kvien TK; Sokka T; Uhlig T; Boonen A;
Ann Rheum Dis; 2014 Nov; 73(11):2010-21. PubMed ID: 23940213
[TBL] [Abstract][Full Text] [Related]
8. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
Cruz-Machado AR; Rodrigues-Manica S; Silva JL; Alho I; Coelho C; Duarte J; Florêncio C; Pimentel-Santos FM; Tavares-Costa J; Vieira-Sousa E
Rheumatology (Oxford); 2020 Nov; 59(11):3158-3171. PubMed ID: 32696064
[TBL] [Abstract][Full Text] [Related]
9. Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study.
Capelusnik D; Zhao SS; Boonen A; Ziade N; Medina CL; Dougados M; Nikiphorou E; Ramiro S
Rheumatology (Oxford); 2022 May; 61(5):2043-2053. PubMed ID: 34387300
[TBL] [Abstract][Full Text] [Related]
10. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.
Zhao SS; Ermann J; Xu C; Lyu H; Tedeschi SK; Liao KP; Yoshida K; Moots RJ; Goodson NJ; Solomon DH
Rheumatology (Oxford); 2019 Nov; 58(11):2025-2030. PubMed ID: 31081033
[TBL] [Abstract][Full Text] [Related]
11. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.
Kiltz U; van der Heijde D; Boonen A; Akkoc N; Bautista-Molano W; Burgos-Vargas R; Wei JC; Chiowchanwisawakit P; Dougados M; Duruoz MT; Elzorkany BK; Gaydukova I; Gensler LS; Gilio M; Grazio S; Gu J; Inman RD; Kim TJ; Navarro-Compan V; Marzo-Ortega H; Ozgocmen S; Pimentel Dos Santos F; Schirmer M; Stebbings S; Van den Bosch FE; van Tubergen A; Braun J
Ann Rheum Dis; 2018 Sep; 77(9):1311-1317. PubMed ID: 29858176
[TBL] [Abstract][Full Text] [Related]
12. Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study.
Putrik P; Ramiro S; Keszei AP; Hmamouchi I; Dougados M; Uhlig T; Kvien TK; Boonen A
Ann Rheum Dis; 2016 Mar; 75(3):540-6. PubMed ID: 25630346
[TBL] [Abstract][Full Text] [Related]
13. Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study.
Nikiphorou E; Ramiro S; van der Heijde D; Norton S; Moltó A; Dougados M; van den Bosch F; Landewé R;
Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1257-1262. PubMed ID: 29125900
[TBL] [Abstract][Full Text] [Related]
14. Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: Analysis of the ASAS-perSpA study.
Zhao SS; Nikiphorou E; Boonen A; López-Medina C; Dougados M; Ramiro S
Semin Arthritis Rheum; 2021 Aug; 51(4):804-812. PubMed ID: 34153894
[TBL] [Abstract][Full Text] [Related]
15. 2018 APLAR axial spondyloarthritis treatment recommendations.
Tam LS; Wei JC; Aggarwal A; Baek HJ; Cheung PP; Chiowchanwisawakit P; Dans L; Gu J; Hagino N; Kishimoto M; Reyes HM; Soroosh S; Stebbings S; Whittle S; Yeap SS; Lau CS
Int J Rheum Dis; 2019 Mar; 22(3):340-356. PubMed ID: 30816645
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
[TBL] [Abstract][Full Text] [Related]
17. Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study.
Derakhshan MH; Goodson NJ; Packham JC; Sengupta R; Molto A; Marzo-Ortega H; Siebert S;
J Rheumatol; 2019 Jul; 46(7):701-709. PubMed ID: 30647169
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project.
López-Medina C; Jiménez-Gómez Y; Moltó A; Schiotis RE; Marzo-Ortega H; van Gaalen FA; Ozgocmen S; Dougados M; Calvo-Gutiérrez J; Castro-Villegas MC; Collantes-Estévez E; Font-Ugalde P;
Joint Bone Spine; 2018 Jul; 85(4):447-453. PubMed ID: 28754402
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
